

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15671 A2

(51) International Patent Classification⁷: A61K 9/70, 47/34

(21) International Application Number: PCT/US00/40772

(22) International Filing Date: 29 August 2000 (29.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/151,509 30 August 1999 (30.08.1999) US

(71) Applicant: TEPHA, INC. [US/US]; 303 Third Street,
Cambridge, MA 02142-1126 (US).

(72) Inventor: WILLIAMS, Simon, F.; 28 Deerfield Road,
Sherborn, MA 01770 (US).

(74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FLUSHABLE DISPOSABLE POLYMERIC PRODUCTS

(57) Abstract: Materials suitable for preparing components of flushable drug delivery systems are described. These components include drug impermeable and drug permeable materials, including materials that can be used to control the rate of release of drugs from the device, and pressure sensitive adhesive compositions which are drug compatible. Methods for fabricating these devices, including transdermal drug delivery patches, are described.

WO 01/15671 A2

FLUSHABLE DISPOSABLE POLYMERIC PRODUCTS

Field of the Invention

The present invention generally relates to drug delivery systems and other polymeric products that they can be disposed of after use by flushing
5 into a toilet.

Background of the Invention

Transdermal drug delivery systems are now commonly used to deliver a variety of types of drugs across the skin. Transdermal delivery systems are particularly useful for the delivery of drugs with low molecular
10 weights and high water solubility, and offer some advantages over other delivery systems. For example, these systems deliver drugs directly to the systemic circulation, by-passing problems sometimes associated with first pass metabolism. The systems are also useful for delivering drugs in a steady-state manner, without producing highs and lows in blood levels, and
15 for providing prolonged delivery times. Examples of transdermal drug delivery systems include formulations designed to deliver anti-anginal glyceryl trinitrate (nitroglycerin), formulations designed to deliver nicotine for smoking cessation, and formulations for hormone replacement therapy (HRT) to treat menopausal symptoms and prophylaxis of osteoporosis.
20 These products are sold under tradenames such as DEPONIT™, DUROGESIC™, ESTRACOMBI™, ESTRADERM™, ESTRAPAK™, EVOREL-PAK™, EVOREL™, FEMATRIX™, MINITRON™, NICONIL™, NICORETTE™, NICOTINEL™L, NITRO-DUR™, NITROLINGAL™, SCOPODERM™, and TRANSIDERM-NITROR™.

25 The initial transdermal patches used one of three approaches to deliver drugs: membrane permeation, multilaminate adhesive dispersion and matrix dispersion. In all three cases the physical appearance of the dosage form resembles an adhesive plaster dressing. The difference in the delivery approach lies in the technique used to retain the drug and control its release.
30 In the membrane permeation approach, a flat packet made with one wall of a drug-impermeable laminate and a second wall made from a rate-controlling membrane is used to hold a reservoir of drug. The membrane is coated

externally with a pressure sensitive adhesive polymer which is drug compatible. In the second approach, the drug is contained in an adhesive polymer and is sandwiched between a drug-impermeable backing support and thin layers of rate-controlling adhesive forming a multilaminate adhesive dispersion. In the matrix diffusion approach, the drug is homogeneously dispersed in a matrix molded in a disc of predefined surface area and thickness.

Improvements in the use of transdermal systems continue to be made, for example, with the use of skin penetration enhancers, electrotransport, as well as systems to deliver different drug types, such as insulin for diabetics, and prostaglandins for treatment of peripheral arterial occlusive disease.

One disadvantage to the use of transdermal drug delivery patches relates to the potential hazards associated with their disposal after use. At the end of their use these transdermal drug delivery patches must be safely discarded. This can be a particular concern if no suitable collection system exists and the patch contains residual active ingredients and/or has become contaminated during use, for example, with bodily fluids. The problem is further compounded by the frequency of use of these patches. Many patches, for example, are applied daily for prolonged periods of time. There is also a further complication involved in disposing of those devices which incorporate electrotransport systems, for example, as described in U.S. Patent No. 5,879,322 to Lattin, et al.

A potentially good method for disposing of transdermal drug delivery patches (and other drug contaminated devices, including simpler devices such as BAND-AIDTM plastic adhesive bandages) in a safe and environmentally acceptable manner could involve flushing these patches down the toilet after use. Unfortunately, while the physical and chemical properties of the components of the current transdermal drug delivery vehicles make them well suited to their task of drug delivery, these components are generally derived from materials which will not degrade in water or sewage. Such disposal could lead to blockages in the sewerage system or subsequent contamination.

It is therefore desirable to have flushable transdermal drug delivery systems which are easier to use and can be disposed of in a safe and environmentally acceptable manner. It is also desirable to have other types of flushable drug delivery systems for the same reasons, including systems used for buccal, vaginal and ophthalmic delivery of drugs, as well as adhesive bandages and coverings.

It is therefore an object of this invention to provide components for preparing flushable drug delivery systems and adhesive bandages:

It is a further object of this invention to provide methods for fabricating flushable drug delivery systems and bandages.

Summary of the Invention

Biodegradable polyhydroxyalkanoate materials suitable for preparing components of flushable drug delivery systems and bandages are described. These components include drug impermeable and drug permeable materials, including materials that can be used to control the rate of release of drugs from the device, and pressure sensitive adhesive compositions which are drug and/or skin compatible. Methods for fabricating these devices, including transdermal drug delivery patches, are described.

Detailed Description of the Invention

Materials for Making Flushable Drug Delivery Systems and Bandages

Materials are described which can be used to prepare components of flushable drug delivery systems and bandages, including the plastic laminates, components of the adhesives, moisture and/or drug barriers, and packaging. These materials will break down in sewage to harmless metabolites. In a preferred embodiment the materials are selected from a group of polymers known as polyhydroxyalkanoates. In another preferred embodiment, the material components can be fabricated alone, or with other components and materials, into flushable transdermal, buccal, vaginal, or ophthalmic drug delivery devices.

A. Polymers

The systems are formed of compositions that are able to break down in an aqueous environment or in sewage to harmless metabolites. In a preferred form, it is desirable for the materials to have a good shelf-life, degrading only after prolonged contact with water or within one year of discharge into the sewage system, preferably within six months of discharge. A particularly preferred class of materials are polyhydroxyalkanoates.

Polyhydroxyalkanoates (PHAs) are a class of naturally occurring polyesters that are synthesized by numerous organisms in response to environmental stress. For reviews, see Byrom, D., "Miscellaneous Biomaterials," in D. Byrom, Ed., "Biomaterials" MacMillan Publishers, London, 1991, pp. 333-359; Hocking, P.J. and Marchessault, R.H. "Biopolyesters", G.J.L. Griffin, Ed., "Chemistry and Technology of Biodegradable Polymers," Chapman and Hall, London, 1994, pp.48-96; Holmes, P.A., "Biologically Produced (R)-3-hydroxyalkanoate Polymers and Copolymers," in D.C. Bassett Ed., "Developments in Crystalline Polymers," Elsevier, London, Vol. 2, 1988, pp. 1-65; Lafferty *et al.*, "Microbial Production of Poly- β -hydroxybutyric acid," H.J. Rehm and G. Reed, Eds., "Biotechnology", Verlagsgesellschaft, Weinheim, Vol. 66, 1988, pp. 135-176; Müller and Seebach, *Angew. Chem. Int. Ed. Engl.* 32:477-502 (1993); Steinbüchel, A. "Polyhydroxyalkanoic Acids," in D. Byrom Ed., "Biomaterials", MacMillan Publishers, London, 1991, pp. 123-213; and, Williams and Peoples, *CHEMTECH*, 26:38-44, (1996).

The PHA biopolymers may be broadly divided into three groups according to the length of their pendant groups and their respective biosynthetic pathways. Those with short pendant groups, such as polyhydroxybutyrate (PHB), a homopolymer of R-3-hydroxybutyric acid (R-3HB) units, are highly crystalline thermoplastic materials, and have been known the longest (Lemoigne, M. and Roukhelman, N., *Annales des fermentations*, 5:527-536 (1925)). A second group of PHAs containing the short R-3HB units randomly polymerized with much longer pendant group hydroxy acid units were first reported in the early seventies (Wallen, L.L.

and Rohwedder, W.K., *Environ. Sci. Technol.*, 8:576-579 (1974)). A number of microorganisms which specifically produce copolymers of R-3HB with these longer pendant group hydroxy acid units are also known and belong to this second group (Steinbüchel, A. and Wiese, S., *Appl. Microbiol. Biotechnol.*, 37:691-697 (1992)). In the early eighties, a research group in The Netherlands identified a third group of PHAs, which contained predominantly longer pendant group hydroxy acids (De Smet, M.J. *et al.*, *J. Bacteriol.*, 154:870-878 (1983)).

The PHA polymers may constitute up to 90% of the dry cell weight of bacteria, and are found as discrete granules inside the bacterial cells. These PHA granules accumulate in response to nutrient limitation and serve as carbon and energy reserve materials. Distinct pathways are used by microorganisms to produce each group of these polymers. One of these pathways leading to the short pendant group polyhydroxyalkanoates (SPGPHAs) involves three enzymes, beta ketothiolase, Acetoacetyl CoA reductase and PHB synthase (sometimes called polymerase). Using this pathway, the homopolymer PHB is synthesized by condensation of two molecules of acetyl-Coenzyme A to give acetoacetyl-Coenzyme A, followed by reduction of this intermediate to R-3-hydroxybutyryl-Coenzyme A, and subsequent polymerization. The last enzyme in this pathway, namely the synthase, has a substrate specificity that can accommodate C3-C5 monomeric units including R-4-hydroxy acid and R-5-hydroxy acid units. This biosynthetic pathway is found, for example, in the bacteria *Zoogloea ramigera* and *Alcaligenes eutrophus*.

The biosynthetic pathway which is used to make the third group of PHAs, namely the long pendant group polyhydroxyalkanoates (LPGPHAs), is still partly unknown, however, it is currently thought that the monomeric hydroxyacyl units leading to the LPGPHAs are derived by the β -oxidation of fatty acids and the fatty acid pathway. The R-3-hydroxyacyl-Coenzyme substrates resulting from these routes are then polymerized by PHA synthases (sometimes called polymerases) that have substrate specificities

favoring the larger monomeric units in the C6-C14 range. Long pendant group PHAs are produced, for example, by *Pseudomonads*.

Presumably, the second group of PHAs containing both short R-3HB units and longer pendant group monomers utilize both the pathways described above to provide the hydroxy acid monomers. The latter are then polymerized by PHA synthases able to accept these units.

In all, about 100 different types of hydroxy acids have been incorporated into PHAs by fermentation methods (Williams, S.F. *et al.*, *Int. J. Biol. Macromol.*, 25:111-121 (1999)). Notably, these include PHAs containing functionalized pendant groups such as esters, double bonds, alkoxy, aromatic, halogens and hydroxy groups.

During the mid-1980's, several research groups were actively identifying and isolating the genes and gene products responsible for PHA synthesis. These efforts have lead to the development of transgenic systems for production of PHAs in both microorganism and plants, as well as enzymatic methods for PHA synthesis. Such routes increase further the available PHA types. These advances have been reviewed in Williams, S.F. and Peoples, O.P., *CHEMTECH*, 26, 38-44 (1996), Madison, L.L and Huisman, G.W. *Microbiol. Mol. Biol. Rev.*, 63:21-53 (1999), and Williams S.F. and Peoples, O.P., *Chem. Br.* 33, 29-32 (1997).

In addition to using biological routes for PHA synthesis, PHA polymers may also be derived by chemical synthesis. One widely used approach involves the ring-opening polymerization of β -lactone monomers using various catalysts or initiators such as aluminoxanes, distannoxanes, or alkoxy-zinc and alkoxy-aluminum compounds (see Agostini, D.E. *et al.*, *Polym. Sci., Part A-1*, 9:2775-2787 (1971); Gross, R.A. *et al.*, *Macromolecules*, 21:2657-2668 (1988); Dubois, P.I. *et al.*, *Macromolecules*, 26:4407-4412 (1993); Le Borgne, A. and Spassky, N., *Polymer*, 30:2312-2319 (1989); Tanahashi, N. and Doi, Y., *Macromolecules*, 24:5732-5733 (1991); Hori, Y.M. *et al.*, *Macromolecules*, 26:4388-4390 (1993); Kemnitzer, J.E. *et al.*, *Macromolecules*, 26:1221-1229 (1993); Hori, Y.M. *et al.*, *Macromolecules*, 26:5533-5534 (1993); Hocking, P.J. and Marchessault,

R.H., *Polym. Bull.*, 30:163-170 (1993): A second approach involves condensation polymerization of esters and is described in U.S. Pat. No. 5,563,239 to Hubbs, J.C. and Harrison, M.N., and references therein.

5 Researchers have also developed chemo-enzymatic methods to prepare PHAs. Xie *et al.*, *Macromolecules*, 30:6997-6998 (1997), for example, have reported a ring opening polymerization of beta-butyrolactone by thermophilic lipases to yield PHB.

One of the most useful properties of PHAs which readily distinguishes them from petrochemical derived polymers is their biodegradability. Produced naturally by soil bacteria, the PHAs are degraded upon subsequent exposure to these same bacteria in either sewage, soil, compost, or marine sediment.

Biodegradation of PHAs is dependent upon a number of factors such as the composition of the PHA, microbial activity of the environment and the surface area of the item. In addition, temperature, pH, molecular weight and crystallinity are important factors. The rate of biodegradation can be controlled by tailoring the composition of the PHA as well as using additives and chemical treatments. Biodegradation starts when microorganisms begin growing on the surface of the plastic and secrete enzymes which break down the polymer into hydroxy acid monomeric units. The hydroxy acids are then taken up by the microorganisms and used as carbon sources for growth. In aerobic environments the polymers are degraded to carbon dioxide and water, whereas in anaerobic environments the degradation products are carbon dioxide and methane (Williams, S.F. and Peoples, O.P., *CHEMTECH*, 26, 38-44 (1996)).

Importantly for use in these drug delivery systems, the PHA polymers have fairly good resistance to water and do not dissolve readily upon contact with water. Only after prolonged exposure, normally to highly basic or acidic aqueous solutions, or in active microbial populations, will these materials break down. It is therefore possible to fabricate drug delivery device components from these polymers that are not only resistant or stable to contact with water, but can also provide moisture vapor and water barrier

properties to the device. One wearing such a device prepared from outer components comprising these materials would therefore be able to wash and bathe without damaging the device, yet the device can be flushed after use and ultimately degrade. If desired the device could also incorporate a biocide.

The water and moisture barrier properties of the PHA polymers can also be beneficial in designing a controlled release device, particularly when it is desirable to protect an active ingredient from water, regulate its exposure to water, and control the rates of release of the active ingredient(s). Multiple barriers can be used to create a device which is "breathable" yet which contains and protects the active ingredient to be delivered.

For medical or veterinary use, the PHA polymers may be sterilized by gamma irradiation or by using ethylene oxide. Certain PHA polymers may also be sterilized in an autoclave with steam.

B. Additives and Chemical Modifiers of the Polymers

A variety of additives can be incorporated into the PHA polymers to improve the properties of the materials. For example, processibility, mechanical, physical, and chemical properties may all be tailored with the use of additives. Colorants may also be added. It is also possible to chemically and physically modify the PHA polymers to optimize their properties for use (and even to covalently attach active ingredients). The polymers can be surface modified with gas plasma and also crosslinked.

C. Other Polymeric Materials

The polyhydroxyalkanoates as a class of polymers offer a wide range of mechanical properties from semi-crystalline thermoplastics to more elastomeric materials. This range of properties is made possible by the ability to prepare the polymers with different types and ratios of monomers (Williams, S.F. and Peoples, O.P., *CHEMTECH*, 26:38-44 (1996)), and Doi, Y., "Microbial Polyesters," VCH Publishers, New York, 1990. It is therefore possible not only to produce PHA materials with mechanical properties similar to those currently used in transdermal patches, but also to expand the range of available mechanical properties.

In addition to the polyhydroxyalkanoates, other materials may be used either alone, with another suitable material, or as blends, to prepare components of flushable drug delivery systems. Suitable materials include for example other polyesters derived from either hydroxy acid units or combinations of diols and diacids. Examples include polymers derived from glycolide, lactide, caprolactone, trimethylene carbonates, succinic acid, glycols, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,3-propanediol, and, dioxanone. Other suitable materials include, but are not limited to certain polyurethanes, polyorthoesters, polyanhydrides, polyvinylacetate, cellulose acetate, polycarbonates, polysaccharides, polyamino acids, polyethylene oxide, and polyvinylalcohol.

D. Materials to be Delivered

The polyhydroxyalkanoates are generally available in two physical forms, namely a latex form (Koosha, F. Ph.D. Dissertation, 1989, Univ. Nottingham, UK., *Diss. Abstr. Int. B* 51:1206 (1990)), and as a dry powder. In the latex form, the PHAs can be used to fabricate a device using aqueous and emulsion processing techniques, whereas the dry powder can be used, for example, in conventional processing techniques, for example, using a solvent or by melt processing.

The PHAs can be encapsulated, be mixed with, or be ionically or covalently coupled to any of a variety of therapeutic, prophylactic or diagnostic agents, either for delivery to a site by the polyhydroxyalkanoate, or to impart properties to the polymer, such as bioadhesion, cell attachment, enhancement of cell growth, inhibition of bacterial growth, and prevention of clot formation.

Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Compounds with a wide range of molecular weight can be encapsulated, for example,

between 100 and 500,000 grams or more per mole. Examples of suitable materials include proteins such as antibodies, receptor ligands, and enzymes, peptides such as adhesion peptides, saccharides and polysaccharides, synthetic organic or inorganic drugs, and nucleic acids. Examples of materials which can be encapsulated include enzymes, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator; antigens for immunization; hormones and growth factors; polysaccharides such as heparin; oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. The polymer can also be used to encapsulate cells and tissues. Representative diagnostic agents are agents detectable by x-ray, fluorescence, magnetic resonance imaging, radioactivity, ultrasound, computer tomography (CT) and positron emission tomography (PET). Ultrasound diagnostic agents are typically a gas such as air, oxygen or perfluorocarbons.

For controlled release, a wide range of different bioactive compounds can be incorporated into the device. These include hydrophobic, hydrophilic, and high molecular weight macromolecules such as proteins. These bioactive compounds may either be covalently or non-covalently incorporated. The release profile may be adjusted by altering one or more of the following parameters: the nature of the PHA; the properties of the bioactive compound; the physical nature of the drug; and the nature of the device. The phrase "nature of the PHA" is used herein to mean, for example, the composition, structure, and molecular weight of the polymer or polymer mixture, including crosslinking and crystallinity. The phrase "properties of the compound" is used herein to mean, for example, the molecular weight, hydrophobicity and hydrophilicity. The phrase "physical nature of the compound" is used herein to mean, for example, the particle size and the loading of the compound.

The bioactive compound is typically incorporated into the PHAs in a percent loading of between 0.1% and 70% by weight, more preferably between 5% and 50% by weight. The phrase "nature of the device" refers to

the device's physical shape, thickness, and form, which may be controlled by the fabrication technique.

E. Bioactive Additives

Other agents may be added to the devices to increase the safety and efficacy of the device. Such agents include but are not limited to compounds with anti-microbial activity, surfactants, steroids, lipids, enzymes, antibodies, fragrances, hormones, anesthetics, and agents enhancing skin penetration.

Methods of Fabricating Flushable Drug Delivery Systems and Components

The materials may be fabricated into flushable drug delivery systems or components thereof using a wide range of processing techniques. Preferred methods of fabricating these systems from the materials include: solvent casting; foaming; leaching; aqueous processing of latex; melt processing, including extrusion, injection, blow, and compression molding; spray drying; and fiber forming and processing, including spinning, extruding, knitting, weaving, and braiding; solvent evaporation; microfluidization; emulsion processing; and the use of lasers and microfabrication techniques. These techniques may be used to fabricate virtually any form, including: films, molded objects, woven and non-woven fabrics, fibers, laminates, impermeable and permeable barriers, dispersions, discs, pockets, reservoirs, including liquid, polymer and solid matrix reservoirs, controlled release devices, matrices, porous structures, microspheres, nanoparticles, microcapsules, pellets, slabs, beads, tubes, and so forth. Representative methods for processing the materials of the invention are described in Holmes, P.A., "Biologically Produced (R)-3-hydroxyalkanoate Polymers and Copolymers," in D.C. Bassett Ed., "Developments in Crystalline Polymers," Elsevier, London, Vol. 2, 1988, pp. 1-65; U.S. Patent No. 4,603,070 to Steel, M.L. and Norton-Berry, P.; U.S. Patent No. 5,502,116 to Noda, I.; and, "Biopol, Properties and Processing," Zeneca Promotional Literature, 1993.

In addition to using the materials to prepare different delivery devices or bandages, they may also be used to prepare pressure sensitive adhesives. Representative methods for preparing pressure sensitive adhesives with the

materials for use in flushable drug delivery systems are described in U.S. Patent Nos. 5,614,576 and 5,753,364 to Rutherford, D.R., Hammar, J. and Babu, G.N. and references described therein, and in WO 95/02649 to Kemmish, D.J. Suitable pressure sensitive adhesives may also be derived

5 from latex formulations of PHA polymers.

Flushable drug delivery systems can be fabricated using the methods and materials described above, and with the procedures and designs described in U.S. Patent No.s. 3,598,122; 3,598,123; 3,731,683; 3,797,494; 4,031,894; 4,201,211; 4,286,592; 4,314,557; 4,379,454; 4,435,180; 4,588,580; 4,559,222; 4,573,995; 4,588,580; 4,645,502; 4,704,282; 10 4,788,062; 4,816,258; 4,849,226; 4,908,027; 4,943,435; 5,814,599; 5,879,322; and, 5,919,478.

Although described herein primarily with reference to drug delivery devices, it is understood that the devices may be used primarily for protective purposes to cover a wound to protect it from water or dirt. These devices 15 may consist solely of the polymeric materials described above, optionally including an adhesive to secure the device at the desired site. Such adhesives are known to those skilled in the art and commonly used in making adhesive bandages.

We claim:

1. A flushable drug delivery device or bandage which degrades after exposure to environmental conditions including water and air, wherein the device or bandage comprises as a structural or adhesive component a polyhydroxyalkanoate.
2. The device of claim 1 wherein the device is manufactured in a form suitable for use as a device selected from the group consisting of a transdermal delivery patch, a buccal delivery device, a vaginal delivery device, or an ophthalmic delivery device.
3. The device of claim 1 wherein the polyhydroxyalkanoate forms a laminate or barrier in the device which breaks down within six to twelve months in an aqueous environment.
4. The device of claim 1 wherein the polyhydroxyalkanoate forms a woven or non-woven fibrous material which breaks down within six to twelve months in an aqueous environment.
5. The device of claim 1 comprising a biodegradable adhesive.
6. The device of claim 5 wherein the adhesive is pressure sensitive.
7. The device of claim 5 wherein the device is an adhesive bandage.
8. The device of claim 5 wherein the adhesive is compatible with a drug or active agent.
9. The device of claim 8 wherein the adhesive can be used to control the rate of release of a drug incorporated into the device.
10. The device of claim 3 wherein the polyhydroxyalkanoate forms a drug impermeable membrane.
11. The device of claim 3 wherein the polyhydroxyalkanoate comprises a drug permeable membrane.
12. The device of claim 11 wherein the membrane can control the rate of drug release from the device.
13. The device of claim 1 wherein the polyhydroxyalkanoate is a copolymer or blend with a polymer selected from the group consisting of polyesters, polyurethanes, polyorthoesters, polyanhydrides, polyvinylacetate,

cellulose acetate, polycarbonate, polysaccharides, polyamino acids, polyethylene oxide, and polyvinylalcohol.

14. The device of claim 2, further comprising an electrotransport system.

15. The device of claim 14 wherein the electrotransport system can be removed prior to flushing the drug delivery component of the transdermal patch.

16. The device of claim 1 further comprising a prophylactic, therapeutic or diagnostic agent.

17. The device of claim 16 wherein the agent is selected from the group consisting of proteins and peptides, sugars and polysaccharides, nucleic acid molecules, and synthetic drugs.

18. A method of use of the device of any of claims 1-17 for drug delivery.

19. A method of use of the device of claims 1-17, to protect a wound.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15671 A3

- (51) International Patent Classification⁷: A61K 9/70, 47/34, A61L 15/62, 15/44, 15/26
- (21) International Application Number: PCT/US00/40772
- (22) International Filing Date: 29 August 2000 (29.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/151,509 30 August 1999 (30.08.1999) US
- (71) Applicant: TEPHA, INC. [US/US]; 303 Third Street, Cambridge, MA 02142-1126 (US).
- (72) Inventor: WILLIAMS, Simon, F.; 28 Deerfield Road, Sherborn, MA 01770 (US).
- (74) Agents: PABST, Patrea, L. et al.; Holland & Knight LLP, One Atlantic Center Suite 2000, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
13 September 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FLUSHABLE DISPOSABLE POLYMERIC PRODUCTS

(57) Abstract: Materials suitable for preparing components of flushable drug delivery systems are described. These components include drug impermeable and drug permeable materials, including materials that can be used to control the rate of release of drugs from the device, and pressure sensitive adhesive compositions which are drug compatible. Methods for fabricating these devices, including transdermal drug delivery patches, are described.

WO 01/15671 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US. 00/40772

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/70 A61K47/34 A61L15/62 A61L15/44 A61L15/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 259 098 A (TAISEI CORPORATION) 13 July 1999 (1999-07-13) page 1, last paragraph -page 3, last paragraph page 6, last paragraph -page 8, paragraph 2; claims; examples & EP 0 945 137 A (TAISEI CORPORATION) 29 September 1999 (1999-09-29)	1-3, 13, 16-18
X	GB 2 166 354 A (ICI PLC) 8 May 1986 (1986-05-08) page 1, line 5 - line 7 page 1, line 40 - line 73 page 2, line 45 - line 48; claims; example 1 -/-	1-4, 16-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

5 March 2001

Date of mailing of the international search report

15/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/40772

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C W POUTON ET AL: "ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL" ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL, vol. 18, 1996, pages 133-162, XP002101840 ISSN: 0169-409X page 134, right-hand column, paragraph 2 page 150, left-hand column, paragraph 2 -page 155, right-hand column, last paragraph	1-4, 16-19
X	US 5 502 116 A (NODA ISAO) 26 March 1996 (1996-03-26) cited in the application column 2, paragraph 2 column 2, paragraph 7 - column 3, line 1 column 3, paragraph 5 - column 4, line 24 column 23, line 40 - column 24, line 1; claims	1,3-8, 13,19
X	WO 98 51812 A (METABOLIX INC) 19 November 1998 (1998-11-19) page 5, line 14 - last line page 18, line 21 - line 24 page 19, line 8 - page 21, line 13 page 22, line 4 - line 29; claims 1,13,17,22-30,41-50,56	1-5,18, 19
X	WO 99 32536 A (METABOLIX INC) 1 July 1999 (1999-07-01) page 1, line 32 - page 2, line 22 page 3, line 8 - line 23 page 18, line 12 - line 18; claims 1,33,35	1-3,18, 19
A	US 4 856 188 A (SIBALIS DAN) 15 August 1989 (1989-08-15) column 1, line 30 - line 38 column 4, line 41 - column 5, line 14 column 5, line 37 - line 52; claim 1	1,14,15

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/40772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2259098 A		NONE	
GB 2166354 A	08-05-1986	NONE	
US 5502116 A	26-03-1996	US 5685756 A US 5747584 A US 5536564 A AU 703156 B AU 1680995 A BR 9506664 A CA 2181795 A CN 1139936 A CZ 9602211 A EP 0741753 A FI 962996 A HU 75182 A, B JP 9508424 T NO 963106 A NZ 279627 A PL 315682 A SG 47812 A SK 96996 A TW 385320 B WO 9520615 A US 5780368 A US 5653930 A ZA 9500657 A	11-11-1997 05-05-1998 16-07-1996 18-03-1999 15-08-1995 16-09-1997 03-08-1995 08-01-1997 15-01-1997 13-11-1996 26-07-1996 28-04-1997 26-08-1997 27-09-1996 26-06-1998 25-11-1996 17-04-1998 04-06-1997 21-03-2000 03-08-1995 14-07-1998 05-08-1997 29-09-1995
WO 9851812 A	19-11-1998	AU 7486798 A EP 0981381 A	08-12-1998 01-03-2000
WO 9932536 A	01-07-1999	AU 1942999 A EP 1042388 A	12-07-1999 11-10-2000
US 4856188 A	15-08-1989	US 4622031 A US 4731926 A US 5167617 A US 5358483 A AT 92775 T AT 168570 T AU 580585 B AU 3935285 A BR 8504939 A CA 1226777 A DE 3587518 A DE 3587518 D DE 3587518 T DE 3588190 D DE 3588190 T EP 0178601 A EP 0197937 A EP 0513879 A IT 1186798 B JP 1828721 C JP 61100264 A KR 9400071 B MX 161423 A WO 8602277 A	11-11-1986 22-03-1988 01-12-1992 25-10-1994 15-08-1993 15-08-1998 19-01-1989 02-05-1986 22-07-1986 15-09-1987 16-09-1993 16-09-1993 02-12-1993 27-08-1998 04-02-1999 23-04-1986 22-10-1986 19-11-1992 16-12-1987 15-03-1994 19-05-1986 05-01-1994 24-09-1990 24-04-1986

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/40772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4856188 A		US 5605536 A	25-02-1997
		US 5653682 A	05-08-1997
		US 5651768 A	29-07-1997
		US 5591123 A	07-01-1997
		US 5976101 A	02-11-1999
		US 5865786 A	02-02-1999
		US 5931804 A	03-08-1999
		US 5224928 A	06-07-1993
		US 4713050 A	15-12-1987
		AT 72132 T	15-02-1992
		AU 591738 B	14-12-1989
		AU 6619386 A	09-06-1988
		BR 8606062 A	15-09-1987
		CA 1267340 A	03-04-1990
		DE 3683737 A	12-03-1992
		EP 0225556 A	16-06-1987
		JP 1964597 C	25-08-1995
		JP 6098192 B	07-12-1994
		JP 62142569 A	25-06-1987
		KR 9403284 B	20-04-1994
		MX 171173 B	06-10-1993
		US 4883457 A	28-11-1989

THIS PAGE BLANK (USPTO)